Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients
Status:
Unknown status
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The investigation is a randomized, double-blind, placebo involved and multi-center clinical
trial. All subjects are assigned to 4 groups, including 3mg, 6mg, 12mg per day and placebo
group. Each group includes 25 subjects, who have hepatic-cellular carcinoma accompanied with
branch vein thrombosis. They receive investigational drug 40 days after resection surgery.
Each cycle lasts 4 to 6 days with an interval of 29 days in all 6 cycles.